• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Export to ExcelExport to Excel
General
Application Number P070026
Most Recent Protocol Version Approved 05/19/2014
Study Name Ceramax PAS
Study Status Progress Inadequate
Study Progress Reason Subject enrollment milestones not met
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) Yes
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The study design is prospective. It includes continued follow-up of premarket cohorts and new enrollment.   show the rest ...
Study Population Description Males and females who are appropriate candidates for primary hip

replacement with non-inflammatory degenerative joint disease.

  show the rest ...
Sample Size A total of 250 Subjects will be enrolled in the investigation

100 subjects recruited from IDE   show the rest ...
Data Collection The main study endpoint is device revision. Secondary endpoints include Harris Hip Score and radiographic   show the rest ...
Followup Visits and Length of Followup Follow-up to 10 years.


Ceramax PAS Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
six month report 06/23/2011 06/23/2011 On Time
18 month report 07/22/2012 07/24/2012 Overdue/Received
two year report 12/22/2012 12/26/2012 Overdue/Received
three year report 12/22/2013 12/20/2013 On Time
four year report 12/22/2014    
five year report 12/22/2015    
six year report 12/21/2016    

Show All Studies

-
-